Fig. 2: Antibody effector function and avidity 2 weeks post final vaccine dose. | npj Vaccines

Fig. 2: Antibody effector function and avidity 2 weeks post final vaccine dose.

From: Impact of adjuvants on the biophysical and functional characteristics of HIV vaccine-elicited antibodies in humans

Fig. 2

A–D Effector Functions. Antibody dependent cellular cytotoxicity-GranToxiLux (ADCC-GTL) area under the curve (AUC) (A), antibody dependent cellular cytotoxicity Luciferase (ADCC-LUC) area under the curve (AUC) (B), Infected Cell Antibody Binding Activity (ICABA) in mean/median fluorescence intensity (MFI) (C), Trogocytosis AUC (D), antibody-dependent cellular phagocytosis (ADCP) score (E), and antibody avidity to SF2 (F) and V1V2 from clade B Case A strain (G). Avidity (F and G) is shown only for participants with a positive vaccine-induced binding response (see Methods for details). Individual vaccine recipients are indicated by dots, and violins plots present group distributions, with median values indicated with a bar.

Back to article page